Merck & Co. Inc.'s anti-PD-1 Keytruda has strong potential in combination with paclitaxel chemotherapy in very early treatment of HER2-negative breast cancer, according to new data, but risks are also emerging in this setting and could have implications for other drugs in the class.
Keytruda (pembrolizumab) is currently approved for lung cancer, melanoma, classical Hodgkin lymphoma, head and neck squamous cell cancer, bladder cancer...